• 1  Al‐Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162. Pubmed link
  • 2  Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 2008;321:5983. Pubmed link
  • 3  Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 2006 Dec;18(6):36274. Cross Ref link Pubmed link
  • 4  Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009 Jun;73(2):34870. Cross Ref link Pubmed link
  • 5  Crequer A, Picard C, Pedergnana V, et al. EVER2 deficiency is associated with mild T‐cell abnormalities. J Clin Immunol 2013 Jan;33(1):1421. Cross Ref link Pubmed link
  • 6  Crequer A, Picard C, Patin E, et al. Inherited MST1 deficiency underlies susceptibility to EV‐HPV infections. PLOS One 2012;7(8):e44010. Cross Ref link Pubmed link
  • 7  Davison SC, Francis N, McLean K, Bunker CB. Epidermodysplasia verruciformis‐like eruption associated with HIV infection. Clin Exp Dermatol 2004 May;29(3):31112. Cross Ref link Pubmed link
  • 8  Hohenstein E, Rady PL, Hergersberg M, et al. Epidermodysplasia verruciformis in a HIV‐positive patient homozygous for the c917A–>T polymorphism in the TMC8/EVER2 gene. Dermatology 2009;218(2):11418. Cross Ref link Pubmed link
  • 9  Jacobelli S, Laude H, Carlotti A, et al. Epidermodysplasia verruciformis in human immunodeficiency virus‐infected patients: a marker of human papillomavirus‐related disorders not affected by antiretroviral therapy. Arch Dermatol 2011 May;147(5):5906. Cross Ref link Pubmed link
  • 10  Rogers HD, Macgregor JL, Nord KM, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009 Feb;60(2):31520. Cross Ref link Pubmed link
  • 11  Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012 Nov;130(5):103048. Cross Ref link Pubmed link
  • 12  Laffort C, Le Deist F, Favre M, et al. Severe cutaneous papillomavirus disease after haemopoietic stem‐cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK‐3 deficiency. Lancet 2004 Jun 19;363(9426):20514. Cross Ref link Pubmed link
  • 13  Gaspar HB, Harwood C, Leigh I, Thrasher AJ. Severe cutaneous papillomavirus disease after haematopoietic stem‐cell transplantation in patients with severe combined immunodeficiency. Br J Haematol 2004 Oct;127(2):2323. Cross Ref link Pubmed link
  • 14  Beaussant Cohen S, Fenneteau O, Plouvier E, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis 2012;7:71. Cross Ref link Pubmed link
  • 15  Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009 Nov 19;361(21):204655. Cross Ref link Pubmed link
  • 16  Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012 Jan;148(1):7984. Cross Ref link Pubmed link
  • 17  Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet 2008 Aug 9;372(9637):489502. Cross Ref link Pubmed link
  • 18  Green HA, Moschella S. Multiple invasive squamous cell carcinomas and common variable immunodeficiency. Arch Dermatol 1992 Mar;128(3):41213. Cross Ref link Pubmed link
  • 19  Vu J, Wallace GR, Singh R, et al. Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol 2007;8(5):30710. Cross Ref link Pubmed link
  • 20  Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott–Aldrich syndrome. Blood 2009 Jun 18;113(25):628895. Cross Ref link Pubmed link
  • 21  Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere biology disorders. Genet Med 2010 Dec;12(12):75364. Cross Ref link Pubmed link
  • 22  Weber F, Fuchs PG, Pfister HJ, Hintner H, Fritsch P, Hoepfl R. Human papillomavirus infection in Netherton's syndrome. Br J Dermatol 2001 May;144(5):10449. Cross Ref link Pubmed link
  • 23  Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population‐based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006 Mar;154(3):498504. Cross Ref link Pubmed link
  • 24  Leigh IM. Progress in skin cancer: the U.K. experience. Br J Dermatol 2014 Sep;171(3):4435. Cross Ref link Pubmed link
  • 25  Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta‐analysis. Lancet 2007 Jul 7;370(9581):5967. Cross Ref link Pubmed link
  • 26  Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS (London) 2009 Jan 28;23(3):38593. Cross Ref link
  • 27  Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non‐AIDS‐defining cancers in HIV‐infected patients. Clin Infect Dis 2012 Nov;55(9):122835. Cross Ref link Pubmed link
  • 28  Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012 Oct;87(10):9911003. Cross Ref link Pubmed link
  • 29  Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV‐infected persons compared with the general population in the United States, 1992–2003. Ann Int Med 2008 May 20;148(10):72836. Cross Ref link Pubmed link
  • 30  Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non‐hodgkin lymphoma among users of systemic glucocorticoids: a p6opulation‐based cohort study. J Natl Cancer Inst 2004 May 5;96(9):70911. Cross Ref link Pubmed link
  • 31  Crum‐Cianflone N, Hullsiek KH, Satter E, et al. Cutaneous malignancies among HIV‐infected persons. Arch Intern Med 2009 Jun 22;169(12):11308. Cross Ref link Pubmed link
  • 32  Silverberg MJ, Leyden W, Warton EM, Quesenberry CP Jr, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non‐melanoma skin cancer. J Natl Cancer Inst 2013 Mar 6;105(5):35060. Cross Ref link Pubmed link
  • 33  Brewer JD, Habermann TM, Shanafelt TD. Lymphoma‐associated skin cancer: incidence, natural history, and clinical management. Int J Dermatol 2014 Mar;53(3):26774. Cross Ref link Pubmed link
  • 34  Lens MB, Newton‐Bishop JA. An association between cutaneous melanoma and non‐Hodgkin's lymphoma: pooled analysis of published data with a review. Ann Oncol 2005 Mar;16(3):4605. Cross Ref link Pubmed link
  • 35  Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non‐Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010 Nov 20;28(33):493544. Cross Ref link Pubmed link
  • 36  Royle JA, Baade PD, Joske D, Girschik J, Fritschi L. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population‐based study. Br J Cancer 2011 Sep 27;105(7):107681. Cross Ref link Pubmed link
  • 37  Onajin O, Brewer JD. Skin cancer in patients with chronic lymphocytic leukemia and non‐Hodgkin lymphoma. Clin Adv Hematol Oncol 2012 Sep;10(9):5716. Pubmed link
  • 38  Brewer JD, Shanafelt TD, Khezri F, et al. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non‐Hodgkin lymphoma: a Rochester Epidemiology Project population‐based study in Minnesota. J Am Acad Dermatol 2015 Feb;72(2):3029. Cross Ref link Pubmed link
  • 39  van den Broek EC, Liu L, Posthuma EF, Janssen‐Heijnen ML, Coebergh JW, Soerjomataram I. Increased risk of chronic lymphocytic leukaemia among cancer survivors in the Netherlands: increased detection, causal factors or both? Ann Hematol 2014 Jan;93(1):15762. Cross Ref link Pubmed link
  • 40  Agnew KL, Ruchlemer R, Catovsky D, Matutes E, Bunker CB. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004 Jun;150(6):112935. Cross Ref link Pubmed link
  • 41  Tomaszewski JM, Lau E, Corry J. Utility of positron emission tomography/computed tomography for nodal staging of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Am J Otolaryngol 2014 Jan–Feb;35(1):669. Cross Ref link Pubmed link
  • 42  Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol 2014 Mar;150(3):2807. Cross Ref link Pubmed link
  • 43  Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001 Sep 15;98(6):197981. Cross Ref link Pubmed link
  • 44  Brewer JD, Shanafelt TD, Otley CC, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population‐based study. J Clin Oncol 2012 Mar 10;30(8):8439. Cross Ref link Pubmed link
  • 45  Saggini A, Anemona L, Chimenti S, et al. HIV‐associated primary cutaneous anaplastic large cell lymphoma: a clinicopathological subset with more aggressive behavior? Case report and review of the literature. J Cutan Pathol 2012 Dec;39(12):11009. Cross Ref link Pubmed link
  • 46  Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006 Dec 20;296(23):282331. Cross Ref link Pubmed link
  • 47  Krynitz B, Edgren G, Lindelof B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008‐A Swedish population‐based study. Int J Cancer 2013 Mar 15;132(6):142938. Cross Ref link Pubmed link
  • 48  Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007 Apr;7(4):9418. Cross Ref link Pubmed link
  • 49  Piselli P, Serraino D, Segoloni GP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer 2013 Jan;49(2):33644. Cross Ref link Pubmed link
  • 50  Harwood CA, Mesher D, McGregor JM, et al. A surveillance model for skin cancer in organ transplant recipients: a 22‐year prospective study in an ethnically diverse population. Am J Transplant 2013 Jan;13(1):11929. Cross Ref link Pubmed link
  • 51  Mudigonda T, Levender MM, O'Neill JL, West CE, Pearce DJ, Feldman SR. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single‐ and multicenter retrospective studies from 2006 to 2010. Dermatol Surg 2013 Mar;39(3):34564. Cross Ref link Pubmed link
  • 52  Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000 Nov 7;102(19 Suppl. 3):III2227. Cross Ref link Pubmed link
  • 53  Bernat Garcia J, Morales Suarez‐Varela M, Vilata JJ, Marquina A, Pallardo L, Crespo J. Risk factors for non‐melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region. Acta Dermato‐Venereol 2013;93(4):4227.
  • 54  Espana A, Redondo P, Fernandez AL, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995 Mar;32(3):45865. Cross Ref link Pubmed link
  • 55  Ferrandiz C, Fuente MJ, Ribera M, et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995 Oct;33(4):5906. Cross Ref link Pubmed link
  • 56  Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996 Oct;10(5):4619. Pubmed link
  • 57  Fuente MJ, Sabat M, Roca J, Lauzurica R, Fernandez‐Figueras MT, Ferrandiz C. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003 Dec;149(6):12216. Cross Ref link Pubmed link
  • 58  Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003 Aug;35(5):171416. Cross Ref link Pubmed link
  • 59  Molina BD, Leiro MG, Pulpon LA, et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transplant Proc 2010 Oct;42(8):30015. Cross Ref link Pubmed link
  • 60  Ducroux E, Boillot O, Ocampo MA, et al. Skin cancers after liver transplantation: retrospective single‐center study on 371 recipients. Transplantation 2014 Aug 15;98(3):33540. Cross Ref link Pubmed link
  • 61  Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 1997 Feb–Mar;29(1–2):82830. Cross Ref link Pubmed link
  • 62  Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 Apr 24;348(17):168191. Cross Ref link Pubmed link
  • 63  Wisgerhof HC, Wolterbeek R, de Fijter JW, Willemze R, Bouwes Bavinck JN. Kidney transplant recipients with cutaneous squamous cell carcinoma have an increased risk of internal malignancy. J Invest Dermatol 2012 Sep;132(9):217683. Cross Ref link Pubmed link
  • 64  Brown VL, Proby CM, Harwood CA, Cerio R. Dermatofibrosarcoma protruberans in a renal transplant recipient. Histopathology 2003 Feb;42(2):198200. Cross Ref link Pubmed link
  • 65  Harwood CA, Leedham‐Green M, Leigh IM, Proby CM. Low‐dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16‐year retrospective study. Arch Dermatol 2005 Apr;141(4):45664. Cross Ref link Pubmed link
  • 66  McCoppin HH, Christiansen D, Stasko T, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Dermatol Surg 2012 Feb;38(2):2309. Cross Ref link Pubmed link
  • 67  Bouwes Bavinck JN, Harwood CA, Genders RE, et al. Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE‐ITSCC PAIN study. Am J Transplant 2014 Mar;14(3):66876. Cross Ref link Pubmed link
  • 68  Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal‐transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004 Feb 27;77(4):5749. Cross Ref link Pubmed link
  • 69  Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006 Apr 27;81(8):1093100. Cross Ref link Pubmed link
  • 70  Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous‐ and basal‐cell carcinomas in kidney‐transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010 May 27;89(10):12318. Cross Ref link Pubmed link
  • 71  Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol 2010 Mar;146(3):2949. Cross Ref link Pubmed link
  • 72  Wehner MR, Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Chren MM. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol 2015 Apr;151(4):3828. Cross Ref link Pubmed link
  • 73  Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN. Incidence and prediction of nonmelanoma skin cancer post‐renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 2003 Mar;41(3):67683. Cross Ref link Pubmed link
  • 74  O'Reilly F, Traywick C, Pennie ML, Foster JK, Chen SC. Baseline quality of life and anxiety in solid organ transplant recipients: a pilot study. Dermatol Surg 2006 Dec;32(12):14805. Cross Ref link Pubmed link
  • 75  Moloney FJ, Keane S, O'Kelly P, Conlon PJ, Murphy GM. The impact of skin disease following renal transplantation on quality of life. Br J Dermatol 2005 Sep;153(3):5748. Cross Ref link Pubmed link
  • 76  Proby CM, Wisgerhof HC, Casabonne D, Green AC, Harwood CA, Bouwes Bavinck JN. The epidemiology of transplant‐associated keratinocyte cancers in different geographical regions. Cancer Treat Res 2009;146:7595. Cross Ref link Pubmed link
  • 77  Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999 Jan;40(1):2734. Cross Ref link Pubmed link
  • 78  Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow‐up study. Transplantation 1996 Mar 15;61(5):71521. Cross Ref link Pubmed link
  • 79  Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sorensen HT. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 2010 Sep;90(5):4749. Cross Ref link Pubmed link
  • 80  Moosa MR. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine 2005 Jan;84(1):1222. Cross Ref link Pubmed link
  • 81  Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988 Feb;84(2):22532. Cross Ref link Pubmed link
  • 82  Qunibi WY, Barri Y, Alfurayh O, et al. Kaposi's sarcoma in renal transplant recipients: a report on 26 cases from a single institution. Transplant Proc 1993 Feb;25(1 Pt 2):14025. Pubmed link
  • 83  Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23‐year experience. Q J Med 2005 Mar;98(3):20514. Cross Ref link
  • 84  Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int 2004 Sep;54(9):64958. Cross Ref link Pubmed link
  • 85  Hsu RB, Chen RJ, Chou NK, Ko WJ, Wang SS, Chu SH. Low incidence of malignancy after transplantation in Chinese heart allograft recipients. Transplant Int 2005 Mar;18(3):2838. Cross Ref link
  • 86  Park GH, Chang SE, Won CH, et al. Incidence of primary skin cancer after organ transplantation: An 18‐year single‐center experience in Korea. J Am Acad Dermatol 2014 Mar;70(3):46572. Cross Ref link Pubmed link
  • 87  Thomson MA, Suggett NR, Nightingale PG, et al. Skin surveillance of a U.K. paediatric transplant population. Br J Dermatol 2007 Jan;156(1):4550. Cross Ref link Pubmed link
  • 88  Koukourgianni F, Harambat J, Ranchin B, et al. Malignancy incidence after renal transplantation in children: a 20‐year single‐centre experience. Nephrol Dial Transplant 2010 Feb;25(2):61116. Cross Ref link Pubmed link
  • 89  Euvrard S, Kanitakis J, Cochat P, Claudy A. Skin cancers following pediatric organ transplantation. Dermatol Surg 2004 Apr;30(4 Pt 2):61621. Pubmed link
  • 90  Euvrard S, Claudy A. Post‐transplant skin cancer: the influence of organ and pre‐transplant disease. Cancer Treat Res 2009;146:6574. Cross Ref link Pubmed link
  • 91  Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010 Aug;10(8):188996. Cross Ref link Pubmed link
  • 92  Wisgerhof HC, van der Boog PJ, de Fijter JW, et al. Increased risk of squamous‐cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients. J Invest Dermatol 2009 Dec;129(12):288694. Cross Ref link Pubmed link
  • 93  Wisgerhof HC, Wolterbeek R, Haasnoot GW, et al. The risk of cancer is not increased in patients with multiple kidney transplantations. Transplant Immunol 2012 Dec;27(4):18994. Cross Ref link
  • 94  Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end‐organ disease. J Am Acad Dermatol 2005 Nov;53(5):78390. Cross Ref link Pubmed link
  • 95  Nissen NN, Barin B, Stock PG. Malignancy in the HIV‐infected patients undergoing liver and kidney transplantation. Curr Opin Oncol 2012 Sep;24(5):51721. Cross Ref link Pubmed link
  • 96  Hibberd AD, Trevillian PR, Wlodarczyk JH, et al. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population‐based retrospective cohort study. Transplantation 2013 Jan 15;95(1):1227. Cross Ref link Pubmed link
  • 97  Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997 Mar 27;336(13):897904. Cross Ref link Pubmed link
  • 98  Hasegawa W, Pond GR, Rifkind JT, et al. Long‐term follow‐up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005 Jan;35(1):515. Cross Ref link Pubmed link
  • 99  Cavalier M, Shmalo JA, Yu M, Billings SD, Abonour R, Nelson RP Jr. Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 2006 Jun;37(12):11038. Cross Ref link Pubmed link
  • 100  Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007 Oct;13(10):112134. Cross Ref link Pubmed link
  • 101  Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006 Mar 1;24(7):111926. Cross Ref link Pubmed link
  • 102  Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009 Jan 29;113(5):117583. Cross Ref link Pubmed link
  • 103  Atsuta Y, Suzuki R, Yamashita T, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft‐versus‐host disease. Ann Oncol 2014 Feb;25(2):43541. Cross Ref link Pubmed link
  • 104  Rork JF, Margossian SP, Nambudiri VE, Huang JT. Nonmelanoma skin cancer in childhood after hematopoietic stem cell transplant: a report of 4 cases. J Pediatr Haematol/Oncol 2014 Apr;36(3):2247. Cross Ref link
  • 105  Beyaert R, Beaugerie L, Van Assche G, et al. Cancer risk in immune‐mediated inflammatory diseases (IMID). Mol Cancer 2013;12(1):98. Cross Ref link Pubmed link
  • 106  Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non‐melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010 Mar;8(3):26874. Cross Ref link Pubmed link
  • 107  Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta‐analysis. Am J Gastroenterol 2014 Feb;109(2):1639. Cross Ref link Pubmed link
  • 108  Abbas AM, Almukhtar RM, Loftus EV Jr, Lichtenstein GR, Khan N. Risk of melanoma and non‐melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014 Nov;109(11):178193. Cross Ref link Pubmed link
  • 109  Peyrin‐Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011 Nov;141(5):162128 e1–5. Cross Ref link Pubmed link
  • 110  Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011 Nov;141(5):161220. Cross Ref link Pubmed link
  • 111  Ramiscal JA, Brewer JD. Thiopurines and risk of nonmelanoma skin cancer in inflammatory bowel disease. JAMA Dermatol 2013 Jan;149(1):924. Cross Ref link Pubmed link
  • 112  Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non‐melanoma skin cancer in an at‐risk population: a cohort study. J Gastroenterol Hepatol 2012 Feb;27(2):3859. Cross Ref link Pubmed link
  • 113  Perrett CM, Macedo C, Francis N, Ion L, Bunker CB. Atypical fibroxanthoma in an HIV‐infected individual. J Cutan Pathol 2011 Apr;38(4):3579. Pubmed link
  • 114  Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012 Aug;143(2):3909 e1. Cross Ref link Pubmed link
  • 115  Williams CJ, Peyrin‐Biroulet L, Ford AC. Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014 Mar;39(5):44758. Cross Ref link Pubmed link
  • 116  van den Reek JM, van Lumig PP, Janssen M, et al. Increased incidence of squamous cell carcinoma of the skin after long‐term treatment with azathioprine in patients with auto‐immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol 2014 Jan;28(1):2733. Cross Ref link Pubmed link
  • 117  Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthr Rheum 2007 Sep;56(9):288695. Cross Ref link
  • 118  Dreyer L, Mellemkjaer L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow‐up study from the DANBIO Registry. Ann Rheum Dis 2013 Jan;72(1):7982. Cross Ref link Pubmed link
  • 119  Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011 Feb;20(2):11930. Cross Ref link Pubmed link
  • 120  Mariette X, Matucci‐Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta‐analysis. Ann Rheum Dis 2011 Nov;70(11):1895904. Cross Ref link Pubmed link
  • 121  Moulis G, Sommet A, Bene J, et al. Cancer risk of anti‐TNF‐alpha at recommended doses in adult rheumatoid arthritis: a meta‐analysis with intention to treat and per protocol analyses. PLOS One 2012;7(11):e48991. Cross Ref link Pubmed link
  • 122  PLEB, Mouterde G, Barnetche T, Morel J, Combe B. Short‐term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol 2012 Apr;39(4):71215. Cross Ref link Pubmed link
  • 123  Mercer LK, Green AC, Galloway JB, et al. The influence of anti‐TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012 Jun;71(6):86974. Cross Ref link Pubmed link
  • 124  Lopez‐Olivo MA, Tayar JH, Martinez‐Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta‐analysis. JAMA 2012 Sep 5;308(9):898908. Cross Ref link Pubmed link
  • 125  Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta‐analysis of randomized controlled trials. J Am Acad Dermatol 2011 Jun;64(6):103550. Cross Ref link Pubmed link
  • 126  Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011 Nov;165(5):95365. Cross Ref link Pubmed link
  • 127  Bouwes Bavinck JN, Euvrard S, Naldi L, et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ‐transplant recipients: a case‐control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol 2007 Jul;127(7):164756. Cross Ref link Pubmed link
  • 128  Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011 Aug;65(2):26379; quiz 80. Cross Ref link Pubmed link
  • 129  Atkar R, Ocampo M, Euvrard S, McGregor J, Kanitakis J, Harwood C. Ultraviolet radiation exposure through window glass may be associated with localization of nonmelanoma skin cancer in organ transplant recipients: a study in France and the UK. Br J Dermatol 2013 Aug;169(2):4845. Cross Ref link Pubmed link
  • 130  McGregor JM, Berkhout RJM, Rozycka M, et al. p53 mutations implicate sunlight in post‐transplant skin cancer irrespective of human papillomavirus status. Oncogene 1997 Oct 2;15(14):173740. Cross Ref link Pubmed link
  • 131  Harwood CA, Attard NR, O'Donovan P, et al. PTCH mutations in basal cell carcinomas from azathioprine‐treated organ transplant recipients. Br J Cancer 2008 Oct 21;99(8):127684. Cross Ref link Pubmed link
  • 132  South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 2014 Oct;134(10):26308. Cross Ref link Pubmed link
  • 133  Lambert SR, Mladkova N, Gulati A, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer 2014 Jan 21;110(2):5209. Cross Ref link Pubmed link
  • 134  Purdie KJ, Harwood CA, Gulati A, et al. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well‐differentiated cutaneous SCCs. J Invest Dermatol 2009 Jun;129(6):15628. Cross Ref link Pubmed link
  • 135  Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008 Nov;8(11):220511. Cross Ref link Pubmed link
  • 136  Dantal J, Hourmant M, Cantarovich D, et al. Effect of long‐term immunosuppression in kidney‐graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998 Feb 28;351(9103):6238. Cross Ref link Pubmed link
  • 137  Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non‐melanoma skin cancer in renal transplant recipients. Lancet 1997 Feb 8;349(9049):398. Cross Ref link Pubmed link
  • 138  Ducloux D, Carron PL, Rebibou JM, et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998 May 15;65(9):12702. Cross Ref link Pubmed link
  • 139  van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010;340:c570. Cross Ref link Pubmed link
  • 140  Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant‐associated immunosuppressants. Arch Dermatol 2001 Apr;137(4):45963. Pubmed link
  • 141  Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant‐associated skin cancer: expert consensus survey. Br J Dermatol 2006 Mar;154(3):395400. Cross Ref link Pubmed link
  • 142  Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000 May 27;69(10):22301. Cross Ref link Pubmed link
  • 143  Locke FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Natl Cancer Inst 2015 Feb;107(2). Cross Ref link Pubmed link
  • 144  Carroll RP, Segundo DS, Hollowood K, et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010 Apr;21(4):71322. Cross Ref link Pubmed link
  • 145  Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012 Dec 1;125(23):55916. Cross Ref link Pubmed link
  • 146  Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case‐control series. J Am Acad Dermatol 2006 Feb;54(2):290300. Cross Ref link Pubmed link
  • 147  Muhleisen B, Petrov I, Gachter T, et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 2009 Jul;55(1):6776. Cross Ref link Pubmed link
  • 148  Kosmidis M, Dziunycz P, Suarez‐Farinas M, et al. Immunosuppression affects CD4(+) mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. J Immunother 2010 Jun;33(5):53846. Cross Ref link Pubmed link
  • 149  Zhang SL, Fujita H, Mitsui H, et al. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLOS One 2013 May 7;8(5).
  • 150  Jung JW, Overgaard NH, Burke MT, et al. Does the nature of residual immune function explain the differential risk of non‐melanoma skin cancer development in immunosuppressed organ transplant recipients? Int J Cancer 2015 Jan 22.
  • 151  Geusau A, Dunkler D, Messeritsch E, et al. Non‐melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. Int J Dermatol 2008 Sep;47(9):91825. Cross Ref link Pubmed link
  • 152  Ingvar A, Smedby KE, Lindelof B, et al. Immunosuppressive treatment after solid organ transplantation and risk of post‐transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010 Aug;25(8):276471. Cross Ref link Pubmed link
  • 153  Doesch AO, Muller S, Konstandin M, et al. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. Transplant Proc 2010 Nov;42(9):36949. Cross Ref link Pubmed link
  • 154  Gallagher MP, Kelly PJ, Jardine M, et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010 May;21(5):8528. Cross Ref link Pubmed link
  • 155  O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transpl 2006 Oct;25(10):118691. Cross Ref link
  • 156  Einollahi B, Nemati E, Lessan‐Pezeshki M, et al. Skin cancer after renal transplantation: Results of a multicenter study in Iran. Ann Transpl 2010 Jul–Sep;15(3):4450.
  • 157  Braconnier P, Del Marmol V, Broeders N, et al. Combined introduction of anti‐IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single‐centre retrospective cohort study. Nephrol Dial Transplant 2012 Jun;27(6):254753. Cross Ref link Pubmed link
  • 158  Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc 2009 Mar;41(2):6723. Cross Ref link Pubmed link
  • 159  Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009 Dec;145(12):13916. Cross Ref link Pubmed link
  • 160  Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post‐transplant malignancy. Clin Transplant 2014 Jun;28(6):63548. Cross Ref link Pubmed link
  • 161  Abou Ayache R, Thierry A, Bridoux F, et al. Long‐term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi‐ or tritherapy. Transplant Proc 2007 Oct;39(8):25924. Cross Ref link Pubmed link
  • 162  Rodriguez‐Peralvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long‐term outcome. J Hepatol 2013 Feb;58(2):26270. Cross Ref link Pubmed link
  • 163  Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous‐cell cancers after hematopoietic stem‐cell transplantation: an international case‐control study. Blood 2005 May 15;105(10):380211. Cross Ref link Pubmed link
  • 164  Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non‐melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001 Sep 1;85(5):6836. Cross Ref link Pubmed link
  • 165  Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non‐Hodgkin's lymphoma: a population‐based case–control study. Br J Cancer 2009 Jan 13;100(1):2005. Cross Ref link Pubmed link
  • 166  Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 2002 Feb;8(2):12835. Cross Ref link Pubmed link
  • 167  de Gruijl FR, Koehl GE, Voskamp P, et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 2010 Aug 15;127(4):796804. Pubmed link
  • 168  Voskamp P, Bodmann CA, Rebel HG, et al. Rapamycin impairs UV induction of mutant‐p53 overexpressing cell clusters without affecting tumor onset. Int J Cancer 2012 Sep 15;131(6):126776. Cross Ref link Pubmed link
  • 169  Sully K, Akinduro O, Philpott MP, et al. The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBalpha isoform signaling. Oncogene 2013 Jul 4;32(27):325462. Cross Ref link Pubmed link
  • 170  Kuschal C, Thoms KM, Schubert S, et al. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp Dermatol 2012 Jan;21(1):26. Cross Ref link Pubmed link
  • 171  Carroll RP, Hester J, Wood KJ, Harden PN. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dialysis Transpl 2013 Feb;28(2):4625. Cross Ref link
  • 172  Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001 Jan;137(1):1420. Cross Ref link Pubmed link
  • 173  Sugie N, Fujii N, Danno K. Cyclosporin‐A suppresses p53‐dependent repair DNA synthesis and apoptosis following ultraviolet‐B irradiation. Photodermatol Photoimmunol Photomed 2002 Aug;18(4):1638. Cross Ref link Pubmed link
  • 174  Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005 Nov;125(5):10205. Cross Ref link Pubmed link
  • 175  Thoms KM, Kuschal C, Oetjen E, et al. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol 2011 Mar;20(3):2326. Cross Ref link Pubmed link
  • 176  Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell‐autonomous mechanism. Nature 1999 Feb 11;397(6719):5304. Cross Ref link Pubmed link
  • 177  Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor‐beta1 expression and promotes tumor progression. Transplantation 2003 Aug 15;76(3):597602. Cross Ref link Pubmed link
  • 178  Duncan FJ, Wulff BC, Tober KL, et al. Clinically relevant immunosuppressants influence UVB‐induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 2007 Dec;7(12):2693703. Cross Ref link Pubmed link
  • 179  Wu X, Nguyen BC, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010 May 20;465(7296):36872. Cross Ref link Pubmed link
  • 180  Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion 2010 Mar;10(2):94101. Cross Ref link Pubmed link
  • 181  Han W, Ming M, He TC, He YY. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem 2010 Apr 9;285(15):1136977. Cross Ref link Pubmed link
  • 182  Xu J, Walsh SB, Verney ZM, Kopelovich L, Elmets CA, Athar M. Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway. Biochem Biophys Res Commun 2011 May 13;408(3):3638. Cross Ref link Pubmed link
  • 183  Walsh SB, Xu J, Xu H, et al. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial‐mesenchymal transition: role of TGFbeta signaling pathway. Mol Carcinogen 2011 Jul;50(7):51627. Cross Ref link
  • 184  Kuschal C, Thoms KM, Boeckmann L, et al. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition. Exp Dermatol 2011 Oct;20(10):7959. Cross Ref link Pubmed link
  • 185  Dziunycz PJ, Lefort K, Wu X, et al. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J Invest Dermatol 2014 Jul;134(7):19982004. Cross Ref link Pubmed link
  • 186  Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB‐UVA irradiation. Br J Dermatol 1987 Oct;117(4):42940. Cross Ref link Pubmed link
  • 187  de Graaf YG, Rebel H, Elghalbzouri A, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008 Apr;17(4):34955. Cross Ref link Pubmed link
  • 188  O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005 Sep 16;309(5742):18714. Cross Ref link Pubmed link
  • 189  Perrett CM, Walker SL, O'Donovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008 Jul;159(1):198204. Cross Ref link Pubmed link
  • 190  Hofbauer GF, Attard NR, Harwood CA, et al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant 2012 Jan;12(1):21825. Cross Ref link Pubmed link
  • 191  Gueranger Q, Li F, Peacock M, et al. Protein oxidation and DNA repair inhibition by 6‐thioguanine and UVA radiation. J Invest Dermatol 2014 May;134(5):140817. Cross Ref link Pubmed link
  • 192  Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients–the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007 May;22 Suppl. 1:i1722. Cross Ref link Pubmed link
  • 193  Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target‐of‐rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 Oct 15;80(7):8839. Cross Ref link Pubmed link
  • 194  Mathew T, Kreis H, Friend P. Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 Aug;18(4):4469. Cross Ref link Pubmed link
  • 195  Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008 Jul;62(2):30513. Cross Ref link Pubmed link
  • 196  Saha B, Cypro A, Martin GM, Oshima J. Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN‐deficient human fibroblasts. Aging Cell 2014 Jun;13(3):5735. Cross Ref link Pubmed link
  • 197  Liu J, Fan HJ, Ma YY, et al. Notch1 Is a 5‐fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLOS One 2013 Feb 7;8(2).
  • 198  Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non‐AIDS‐defining cancers in people with HIV infection. J Clin Oncol 2009 Feb 20;27(6):88490. Cross Ref link Pubmed link
  • 199  Davidovitz Y, Ballin A, Meytes D. Flare‐up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia. Acta Haematol 1997;98(1):446. Cross Ref link Pubmed link
  • 200  Callea V, Brugiatelli M, Stelitano C, Gentile M, Nobile F, Morabito F. Incidence of second neoplasia in patients with B‐cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymph 2006 Nov;47(11):231420. Cross Ref link
  • 201  Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma editorial comment. J Urol 2009 Jul;182(1):14950.
  • 202  Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010 Jan;62(1):317. Cross Ref link Pubmed link
  • 203  Williams K, Mansh M, Chin‐Hong P, Singer J, Arron ST. Voriconazole‐associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014 Apr;58(7):9971002. Cross Ref link Pubmed link
  • 204  Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transpl 2010 Nov;29(11):12404. Cross Ref link
  • 205  Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012 Aug;38(8):136974. Cross Ref link Pubmed link
  • 206  Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transpl 2012 Jul;31(7):6949. Cross Ref link
  • 207  Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long‐term voriconazole. J Heart Lung Transpl 2012 Nov;31(11):117781. Cross Ref link
  • 208  Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole‐related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis 2013 Dec;57(12):e1828. Cross Ref link Pubmed link
  • 209  Mascitelli L, Pezzetta F, Goldstein MR. Why statin therapy may increase the risk for posttransplantation squamous cell carcinoma. Transplant Immunol 2010 Aug;23(4):2245. Cross Ref link
  • 210  Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a meta‐analysis. Br J Cancer 2014 Feb 4;110(3):8027. Cross Ref link Pubmed link
  • 211  Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non‐melanoma skin cancer: a population‐based case–control study. J Invest Dermatol 2013 Aug;133(8):19505. Cross Ref link Pubmed link
  • 212  Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and nonsteroidal anti‐inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta‐analysis. J Invest Dermatol 2015 Apr;135(4):97583. Cross Ref link Pubmed link
  • 213  Zhang B, Liang X, Ye L, Wang Y. No chemopreventive effect of nonsteroidal anti‐inflammatory drugs on nonmelanoma skin cancer: evidence from meta‐analysis. PLOS One 2014;9(5):e96887. Cross Ref link Pubmed link
  • 214  Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011 Aug;131(8):174553. Cross Ref link Pubmed link
  • 215  Aldabagh B, Angeles JGC, Cardones AR, Arron ST. Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol Surg 2013 Jan;39(1):123. Cross Ref link Pubmed link
  • 216  Quint KD, Genders RE, de Koning MN, et al. Human beta‐papillomavirus infection and keratinocyte carcinomas. J Pathol 2015 Jan;235(2):34254. Cross Ref link Pubmed link
  • 217  Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010 May 25;401(1):709. Cross Ref link Pubmed link
  • 218  Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol 2014 Dec;234(4):4315. Cross Ref link Pubmed link
  • 219  Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 2014 Mar 20;32(14):1595601. Cross Ref link Pubmed link
  • 220  Marur S, D'Souza G, Westra WH, Forastiere AA. HPV‐associated head and neck cancer: a virus‐related cancer epidemic. Lancet Oncol 2010 Aug;11(8):7819. Cross Ref link Pubmed link
  • 221  Kreuter A, Gambichler T, Pfister H, Wieland U. Diversity of human papillomavirus types in periungual squamous cell carcinoma. Br J Dermatol 2009 Dec;161(6):12629. Cross Ref link Pubmed link
  • 222  Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009 Oct 15;125(8):175563. Cross Ref link Pubmed link
  • 223  Caldeira S, Zehbe I, Accardi R, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003 Feb;77(3):2195206. Cross Ref link Pubmed link
  • 224  Westphal K, Akgul B, Storey A, Nindl I. Cutaneous human papillomavirus E7 type‐specific effects on differentiation and proliferation of organotypic skin cultures. Cell Oncol 2009;31(3):21326. Pubmed link
  • 225  Accardi R, Dong W, Smet A, et al. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 2006 Mar;7(3):33440. Cross Ref link Pubmed link
  • 226  Cornet I, Bouvard V, Campo MS, et al. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol 2012 Feb;86(4):236670. Cross Ref link Pubmed link
  • 227  Bedard KM, Underbrink MP, Howie HL, Galloway DA. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP‐dependent mechanism and prolong the lifespan of primary keratinocytes. J Virol 2008 Apr;82(8):3894902. Cross Ref link Pubmed link
  • 228  Iftner T, Elbel M, Schopp B, et al. Interference of papillomavirus E6 protein with single–strand break repair by interaction with XRCC1. EMBO J 2002 Sep 2;21(17):47418. Cross Ref link Pubmed link
  • 229  Giampieri S, Storey A. Repair of UV‐induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004 Jun 1;90(11):22039. Pubmed link
  • 230  Wallace NA, Robinson K, Howie HL, Galloway DA. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLOS Pathogens 2012;8(7):e1002807. Cross Ref link Pubmed link
  • 231  Wallace NA, Robinson K, Galloway DA. Beta human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability. J Virol 2014 Jun;88(11):611227. Cross Ref link Pubmed link
  • 232  Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of Bak in UV‐induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000 Dec 1;14(23):306573. Cross Ref link Pubmed link
  • 233  Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 2008 Nov;82(21):1040817. Cross Ref link Pubmed link
  • 234  Struijk L, van der Meijden E, Kazem S, et al. Specific betapapillomaviruses associated with squamous cell carcinoma of the skin inhibit UVB‐induced apoptosis of primary human keratinocytes. J Gen Virol 2008 Sep;89(Pt 9):230314. Cross Ref link Pubmed link
  • 235  Muench P, Probst S, Schuetz J, et al. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53‐mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 2010 Sep 1;70(17):691324. Cross Ref link Pubmed link
  • 236  Howie HL, Koop JI, Weese J, et al. Beta‐HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLOS Pathogens 2011 Aug;7(8):e1002211. Cross Ref link Pubmed link
  • 237  Hussain I, Fathallah I, Accardi R, et al. NF‐kappaB protects human papillomavirus type 38 E6/E7‐immortalized human keratinocytes against tumor necrosis factor alpha and UV‐mediated apoptosis. J Virol 2011 Sep;85(17):901322. Cross Ref link Pubmed link
  • 238  Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, Dutta A. Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60‐dependent transcriptional regulation and apoptotic pathway. Mol Cell 2010 Jun 11;38(5):70011. Cross Ref link Pubmed link
  • 239  Muschik D, Braspenning‐Wesch I, Stockfleth E, Rosl F, Hofmann TG, Nindl I. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLOS One 2011;6(11):e27655. Cross Ref link Pubmed link
  • 240  Cordano P, Gillan V, Bratlie S, et al. The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology 2008 Aug 1;377(2):40818. Cross Ref link Pubmed link
  • 241  Akgul B, Garcia‐Escudero R, Ghali L, et al. The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res 2005 Mar 15;65(6):221623. Cross Ref link Pubmed link
  • 242  Connolly K, Manders P, Earls P, Epstein RJ. Papillomavirus‐associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Cancer Treatment Rev 2014 Mar;40(2):20514. Cross Ref link
  • 243  Mendoza JA, Jacob Y, Cassonnet P, Favre M. Human papillomavirus type 5 E6 oncoprotein represses the transforming growth factor beta signaling pathway by binding to SMAD3. J Virol 2006 Dec;80(24):124204. Cross Ref link Pubmed link
  • 244  Akgul B, Bostanci N, Westphal K, et al. Human papillomavirus 5 and 8 E6 downregulate interleukin‐8 secretion in primary human keratinocytes. J Gen Virol 2010 Apr;91(Pt 4):88892. Cross Ref link Pubmed link
  • 245  Schaper ID, Marcuzzi GP, Weissenborn SJ, et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005 Feb 15;65(4):1394400. Cross Ref link Pubmed link
  • 246  Pfefferle R, Marcuzzi GP, Akgul B, et al. The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol 2008 Sep;128(9):231015. Cross Ref link Pubmed link
  • 247  Marcuzzi GP, Hufbauer M, Kasper HU, Weissenborn SJ, Smola S, Pfister H. Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV‐light exposure and wounding. J Gen Virol 2009 Dec;90(Pt 12):285564. Cross Ref link Pubmed link
  • 248  Storey A, Simmonds M. Interaction between ultraviolet radiation and human papillomavirus. Cancer Treat Res 2009;146:15967. Cross Ref link Pubmed link
  • 249  Feltkamp MC, de Koning MN, Bavinck JN, Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 2008 Dec;43(4):35360. Cross Ref link Pubmed link
  • 250  Wang SJ, Gu W. To be, or not to be: functional dilemma of p53 metabolic regulation. Curr Opin Oncol 2014 Jan;26(1):7885. Cross Ref link Pubmed link
  • 251  Harwood CA, Proby CM. Human papillomaviruses and non‐melanoma skin cancer. Curr Opin Infect Dis 2002 Apr;15(2):10114. Cross Ref link Pubmed link
  • 252  Arron ST, Jennings L, Nindl I, et al. Viral oncogenesis and its role in nonmelanoma skin cancer. Br J Dermatol 2011 Jun;164(6):120113. Cross Ref link Pubmed link
  • 253  Frazer IH. The actinic keratosis virome: can we prevent squamous cell carcinoma with a vaccine? Curr Prob Dermatol 2015;46:2835. Cross Ref link
  • 254  de Koning MN, Weissenborn SJ, Abeni D, et al. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol 2009 Jul;90(Pt 7):161121. Cross Ref link Pubmed link
  • 255  Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLOS Pathogens 2008 Jun;4(6):e1000091. Cross Ref link Pubmed link
  • 256  Waterboer T, Neale R, Michael KM, et al. Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. J Gen Virol 2009 Aug;90(Pt 8):198698. Cross Ref link Pubmed link
  • 257  Harwood CA, Surentheran T, McGregor JM, et al. Human papillomavirus infection and non‐melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000 Jul;61(3):28997. Cross Ref link Pubmed link
  • 258  Purdie KJ, Surentheran T, Sterling JC, et al. Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol 2005 Jul;125(1):98107. Cross Ref link Pubmed link
  • 259  Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus‐DNA loads in actinic keratoses exceed those in non‐melanoma skin cancers. J Invest Dermatol 2005 Jul;125(1):937. Cross Ref link Pubmed link
  • 260  Waterboer T, Abeni D, Sampogna F, et al. Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol 2008 Aug;159(2):4579. Cross Ref link Pubmed link
  • 261  Karagas MR, Waterboer T, Li Z, et al. Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case–control study. BMJ 2010;341:c2986. Cross Ref link Pubmed link
  • 262  Proby CM, Harwood CA, Neale RE, et al. A case–control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011 Jul;11(7):1498508. Cross Ref link Pubmed link
  • 263  Andersson K, Waterboer T, Kirnbauer R, et al. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev 2008 Jan;17(1):18995. Cross Ref link Pubmed link
  • 264  Genders RE, Mazlom H, Michel A, et al. The presence of betapapillomavirus antibodies around transplantation predicts the development of keratinocyte carcinoma in organ transplant recipients: a cohort study. J Invest Dermatol 2015 May;135(5):127582. Cross Ref link Pubmed link
  • 265  Ganzenmueller T, Yakushko Y, Kluba J, Henke‐Gendo C, Gutzmer R, Schulz TF. Next‐generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma. Int J Cancer 2012 Oct 1;131(7):E11739. Cross Ref link Pubmed link
  • 266  Savani BN, Goodman S, Barrett AJ. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res 2009 Apr 1;15(7):221921. Cross Ref link Pubmed link
  • 267  Vinzon SE, Braspenning‐Wesch I, Muller M, et al. Protective vaccination against papillomavirus‐induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model. PLOS Pathogens 2014 Feb;10(2):e1003924. Cross Ref link Pubmed link
  • 268  Marcuzzi GP, Awerkiew S, Hufbauer M, et al. Tumor prevention in HPV8 transgenic mice by HPV8‐E6 DNA vaccination. Med Microbiol Immunol 2014 Jun;203(3):15563. Cross Ref link Pubmed link
  • 269  Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant 2013 Sep;13(9):241117. Cross Ref link Pubmed link
  • 270  Binstock M, Hafeez F, Metchnikoff C, Arron ST. Single‐nucleotide polymorphisms in pigment genes and nonmelanoma skin cancer predisposition: a systematic review. Br J Dermatol 2014 Oct;171(4):71321. Cross Ref link Pubmed link
  • 271  Andresen PA, Nymoen DA, Kjaerheim K, Leivestad T, Helsing P. Susceptibility to cutaneous squamous cell carcinoma in renal transplant recipients associates with genes regulating melanogenesis independent of their role in pigmentation. Biomark Cancer 2013;5:417. Cross Ref link Pubmed link
  • 272  McGregor JM, Harwood CA, Brooks L, et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002 Jul;119(1):8490. Cross Ref link Pubmed link
  • 273  Marshall SE, Bordea C, Haldar NA, et al. Glutathione S‐transferase polymorphisms and skin cancer after renal transplantation. Kidney Int 2000 Nov;58(5):218693. Cross Ref link Pubmed link
  • 274  Ramsay HM, Harden PN, Reece S, et al. Polymorphisms in glutathione S‐transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001 Aug;117(2):2515. Cross Ref link Pubmed link
  • 275  Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin‐10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003 Jan;120(1):99103. Cross Ref link Pubmed link
  • 276  Lira MG, Mazzola S, Tessari G, et al. Association of functional gene variants in the regulatory regions of COX‐2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol 2007 Jul;157(1):4957. Cross Ref link Pubmed link
  • 277  Laing ME, Dicker P, Moloney FJ, et al. Association of methylenetetrahydrofolate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant patients. Transplantation 2007 Jul 15;84(1):11316. Cross Ref link Pubmed link
  • 278  Laing ME, Cummins R, O'Grady A, O'Kelly P, Kay EW, Murphy GM. Aberrant DNA methylation associated with MTHFR C677T genetic polymorphism in cutaneous squamous cell carcinoma in renal transplant patients. Br J Dermatol 2010 Aug;163(2):34552. Cross Ref link Pubmed link
  • 279  Begnini A, Tessari G, Turco A, et al. PTCH1 gene haplotype association with basal cell carcinoma after transplantation. Br J Dermatol 2010 Aug;163(2):36470. Cross Ref link Pubmed link
  • 280  Laing ME, Kay E, Conlon P, Murphy GM. Genetic factors associated with skin cancer in renal transplant patients. Photodermatol Photoimmunol Photomed 2007 Apr–Jun;23(2–3):627. Cross Ref link Pubmed link
  • 281  Tartaglia S, Belloni‐Fortina A, Stefano P, et al. The +61 A‐G polymorphism of the epidermal growth factor gene is not associated with occurrence of non‐melanocytic skin tumors in transplant recipients. J Dermatol Sci 2007 May;46(2):1479. Cross Ref link Pubmed link
  • 282  Perrett CM, Harwood CA, McGregor JM, Warwick J, Cerio R, Karran P. Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. Br J Dermatol 2010 Apr;162(4):73242. Cross Ref link Pubmed link
  • 283  Foss Abrahamsen A, Andersen A, Nome O, et al. Long‐term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow‐up time. Ann Oncol 2002 Nov;13(11):178691. Cross Ref link Pubmed link
  • 284  Janin A, Murata H, Leboeuf C, et al. Donor‐derived oral squamous cell carcinoma after allogeneic bone marrow transplant. Blood 2009 Feb 19;113(8):183440. Cross Ref link Pubmed link
  • 285  Aractingi S, Kanitakis J, Euvrard S, et al. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res 2005 Mar 1;65(5):175560. Cross Ref link Pubmed link
  • 286  Verneuil L, Varna M, Ratajczak P, et al. Human skin carcinoma arising from kidney transplant‐derived tumor cells. J Clin Invest 2013 Sep;123(9):3797801. Cross Ref link Pubmed link
  • 287  Barozzi P, Luppi M, Facchetti F, et al. Post‐transplant Kaposi sarcoma originates from the seeding of donor‐derived progenitors. Nature Med 2003 May;9(5):55461. Cross Ref link Pubmed link
  • 288  Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA. Approach to the treatment of cutaneous malignancy in HIV‐infected patients. Dermatol Ther 2005 Jan–Feb;18(1):7786. Cross Ref link Pubmed link
  • 289  Casabonne D, Lally A, Mitchell L, et al. A case–control study of cutaneous squamous cell carcinoma among Caucasian organ transplant recipients: the role of antibodies against human papillomavirus and other risk factors. Int J Cancer 2009 Oct 15;125(8):193545. Cross Ref link Pubmed link
  • 290  Joly P, Bastuji‐Garin S, Frances C, et al. Squamous cell carcinomas are associated with verrucokeratotic cutaneous lesions but not with common warts in organ‐transplant patients. A case–control study. Transplantation 2010 May 27;89(10):122430. Cross Ref link Pubmed link
  • 291  Bouwes Bavinck JN, Neale RE, Abeni D, et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 2010 Dec 1;70(23):977786. Cross Ref link Pubmed link
  • 292  Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non‐melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002 Nov;147(5):9506. Cross Ref link Pubmed link
  • 293  Smith L, Dahler AL, Cavanagh LL, et al. Modulation of proliferation‐specific and differentiation‐specific markers in human keratinocytes by SMAD7. Exp Cell Res 2004 Apr 1;294(2):35665. Cross Ref link Pubmed link
  • 294  Cooper SM, Wojnarowska F. The accuracy of clinical diagnosis of suspected premalignant and malignant skin lesions in renal transplant recipients. Clin Exp Dermatol 2002 Sep;27(6):4368. Cross Ref link Pubmed link
  • 295  Kwatra SG, Mills KC, Zeitany A, et al. Pain and nonmelanoma skin cancer in transplant patients. J Am Acad Dermatol 2012 Dec;67(6):13878. Cross Ref link Pubmed link
  • 296  Stoff B, Salisbury C, Parker D, O'Reilly Zwald F. Dermatopathology of skin cancer in solid organ transplant recipients. Transpl Rev (Orlando) 2010 Oct;24(4):17289. Cross Ref link
  • 297  Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006 Oct;126(10):230815. Cross Ref link Pubmed link
  • 298  Boukamp P. Non‐melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005 Oct;26(10):165767. Cross Ref link Pubmed link
  • 299  Jacobs MS, Persons DL, Fraga GR. EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study. J Cutan Pathol 2013 May;40(5):44754. Cross Ref link Pubmed link
  • 300  Poligone B, Hayden MS, Chen LJ, Pentland AP, Jimi E, Ghosh S. A role for NF‐kappa B activity in skin hyperplasia and the development of keratoacanthomata in mice. PLOS One 2013 Aug 19;8(8). Cross Ref link Pubmed link
  • 301  Goudie DR, D'Alessandro M, Merriman B, et al. Multiple self‐healing squamous epithelioma is caused by a disease‐specific spectrum of mutations in TGFBR1. Nat Genet 2011 Apr;43(4):3659. Cross Ref link Pubmed link
  • 302  Hua HK, Jin C, Yang LJ, Tao SQ, Zhu XH. Expression of cyclooxygenase‐2 in squamous cell carcinoma and keratoacanthoma and its clinical significance. Cell Biochem Biophys 2015 Jan 10. Pubmed link
  • 303  Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010 Sep 27;90(6):6837. Cross Ref link Pubmed link
  • 304  Metchnikoff C, Mully T, Singer JP, Golden JA, Arron ST. The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. J Am Acad Dermatol 2012 Nov;67(5):82935. Cross Ref link Pubmed link
  • 305  Buell JF, Hanaway MJ, Thomas M, Alloway RR, Woodle ES. Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005 Mar;37(2):9623. Cross Ref link Pubmed link
  • 306  Southwell KE, Chaplin JM, Eisenberg RL, McIvor NP, Morton RP. Effect of immunocompromise on metastatic cutaneous squamous cell carcinoma in the parotid and neck. Head Neck J 2006 Mar;28(3):2448. Cross Ref link
  • 307  Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003 Mar;139(3):3016. Cross Ref link Pubmed link
  • 308  Carucci JA, Martinez JC, Zeitouni NC, et al. In‐transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg 2004 Apr;30(4 Pt 2):6515. Pubmed link
  • 309  Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol 2006 Jun;142(6):7558. Pubmed link
  • 310  Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999 Apr 15;85(8):175864. Cross Ref link Pubmed link
  • 311  Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo cancer‐related death in Australian liver and cardiothoracic transplant recipients. Am J Transplant 2013 May;13(5):1296304. Cross Ref link Pubmed link
  • 312  Wilson ML, Elston DM, Tyler WB, Marks VJ, Ferringer T. Dense lymphocytic infiltrates associated with non‐melanoma skin cancer in patients with chronic lymphocytic leukemia. Dermatol Online J 2010;16(3):4. Pubmed link
  • 313  Verburg M, Lang M, Muhlstadt M, et al. Cutaneous squamous cell carcinoma with perineural invasion: report on eight cases and review of the literature. Dermatology 2015;230(2):13542. Cross Ref link Pubmed link
  • 314  Nguyen P, Vin‐Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002 Jun;138(6):75863. Cross Ref link Pubmed link
  • 315  Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of Basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukemia. Arch Dermatol 2004 Aug;140(8):9858. Cross Ref link Pubmed link
  • 316  Chen CH, Chung CY, Wang LH, Lin C, Lin HL, Lin HC. Risk of cancer among HIV‐infected patients from a population‐based nested case–control study: implications for cancer prevention. BMC Cancer 2015;15:133. Cross Ref link Pubmed link
  • 317  Euvrard S, Kanitakis J, Pouteil‐Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995 Aug;33(2 Pt 1):2229. Cross Ref link Pubmed link
  • 318  Ulrich C. Topical treatment of field cancerization. Cancer Treat Res 2009;146:43946. Cross Ref link Pubmed link
  • 319  Wallingford SC, Russell SA, Vail A, Proby CM, Lear JT, Green AC. Actinic keratoses, actinic field change and associations with squamous cell carcinoma in renal transplant recipients in Manchester, UK. Acta Derm Venereol 2015 Mar 18. Pubmed link
  • 320  Boyd AS, Stasko T, Cameron GS, Russell M, King LE Jr. Histologic features of actinic keratoses in solid organ transplant recipients and healthy controls. J Am Acad Dermatol 2001 Aug;45(2):21721. Cross Ref link Pubmed link
  • 321  Kanitakis J. Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features. Eur J Dermatol 2014 Sep–Oct;24(5):53344. Pubmed link
  • 322  Herranz P, Pizarro A, De Lucas R, et al. High incidence of porokeratosis in renal transplant recipients. Br J Dermatol 1997 Feb;136(2):1769. Cross Ref link Pubmed link
  • 323  Proby C, Harwood C. Porokeratosis in organ transplantation recipients. In: Otley CC, Stasko T, eds. Skin Disease in Organ Transplantation. Cambridge: Cambridge University Press, 2008:11921. Cross Ref link
  • 324  Silver SG, Crawford RI. Fatal squamous cell carcinoma arising from transplant‐associated porokeratosis. J Am Acad Dermatol 2003 Nov;49(5):9313. Cross Ref link Pubmed link
  • 325  Anzai S, Takeo N, Yamaguchi T, et al. Squamous cell carcinoma in a renal transplant recipient with linear porokeratosis. J Dermatol 1999 Apr;26(4):2447. Cross Ref link Pubmed link
  • 326  Kanitakis J, Alhaj‐Ibrahim L, Euvrard S, Claudy A. Basal cell carcinomas developing in solid organ transplant recipients: clinicopathologic study of 176 cases. Arch Dermatol 2003 Sep;139(9):11337. Cross Ref link Pubmed link
  • 327  Valery PC, Neale R, Williams G, Pandeya N, Siller G, Green A. The effect of skin examination surveys on the incidence of basal cell carcinoma in a Queensland community sample: a 10‐year longitudinal study. J Investig Dermatol Symp Proc 2004 Mar;9(2):14851. Cross Ref link Pubmed link
  • 328  Oram Y, Orengo I, Griego RD, Rosen T, Thornby J. Histologic patterns of basal cell carcinoma based upon patient immunostatus. Dermatol Surg 1995 Jul;21(7):61114. Pubmed link
  • 329  de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes? J Am Acad Dermatol 1996 Nov;35(5 Pt 1):6969. Cross Ref link Pubmed link
  • 330  Gordon Spratt EA, Fischer M, Kamino H. Eruptive basal‐cell carcinomas in the setting of human immunodeficiency virus infection. Dermatol Online J 2012 Dec;18(12):1. Pubmed link
  • 331  Hausauer AK, Maurer T, Leslie KS, Parvataneni R, Stuart SE, Chren MM. Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus. JAMA Dermatol 2013 Feb;149(2):23941. Cross Ref link Pubmed link
  • 332  Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005 Nov 1;104(9):19627. Cross Ref link Pubmed link
  • 333  Dahlke E, Murray CA, Kitchen J, Chan AW. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transpl Res 2014;3:10. Cross Ref link
  • 334  Matin RN, Mesher D, Proby CM, et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant 2008 Sep;8(9):1891900. Cross Ref link Pubmed link
  • 335  Brewer JD, Christenson LJ, Weaver AL, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol 2011 Jul;147(7):7906. Cross Ref link Pubmed link
  • 336  Vajdic CM, Chong AH, Kelly PJ, et al. Survival after cutaneous melanoma in kidney transplant recipients: a population‐based matched cohort study. Am J Transplant 2014 Jun;14(6):136875. Cross Ref link Pubmed link
  • 337  Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996 Jan 27;61(2):2748. Cross Ref link Pubmed link
  • 338  Dapprich DC, Weenig RH, Rohlinger AL, et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol 2008 Sep;59(3):40517. Cross Ref link Pubmed link
  • 339  Xiao D, Craig JC, Chapman JR, Dominguez‐Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant 2013 Oct;13(10):264552. Cross Ref link Pubmed link
  • 340  Penn I. Transmission of cancer from organ donors. Ann Transpl 1997;2(4):712.
  • 341  Morris‐Stiff G, Steel A, Savage P, et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant 2004 Mar;4(3):4446. Cross Ref link Pubmed link
  • 342  Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010 Aug;11(8):7906. Cross Ref link Pubmed link
  • 343  MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003 Feb 6;348(6):5678. Cross Ref link Pubmed link
  • 344  Kim JK, Carmody IC, Cohen AJ, Loss GE. Donor transmission of malignant melanoma to a liver graft recipient: case report and literature review. Clin Transplant 2009 Aug–Sep;23(4):5714. Cross Ref link Pubmed link
  • 345  Bajaj NS, Watt C, Hadjiliadis D, et al. Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection. Transplant Int 2010 Jul;23(7):e2631. Cross Ref link
  • 346  Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic I kappa B kinase activity in diffuse large B‐cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014 Aug 5;111(31):1136570. Cross Ref link Pubmed link
  • 347  Ulrich C, Jurgensen JS, Degen A, et al. Prevention of non‐melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case‐control study. Br J Dermatol 2009 Nov;161 Suppl. 3:7884. Cross Ref link Pubmed link
  • 348  Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non‐AIDS‐defining cancers among human immunodeficiency virus‐infected individuals. Cancer 2005 Oct 1;104(7):150511. Cross Ref link Pubmed link
  • 349  Famenini S, Martires KJ, Zhou H, Xavier MF, Wu JJ. Melanoma in patients with chronic lymphocytic leukemia and non‐Hodgkin lymphoma. J Am Acad Dermatol 2015 Jan;72(1):7884. Cross Ref link Pubmed link
  • 350  McGregor JM, Barker JN, MacDonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 1991 Mar;16(2):1312. Cross Ref link Pubmed link
  • 351  Smith CH, McGregor JM, Barker JN, Morris RW, Rigden SP, MacDonald DM. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993 Jan;28(1):515. Cross Ref link Pubmed link
  • 352  Grob JJ, Bastuji‐Garin S, Vaillant L, et al. Excess of nevi related to immunodeficiency: a study in HIV‐infected patients and renal transplant recipients. J Invest Dermatol 1996 Nov;107(5):6947. Cross Ref link Pubmed link
  • 353  Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 1988 Mar;13(2):1235. Cross Ref link Pubmed link
  • 354  Alaibac M, Piaserico S, Rossi CR, et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 2003 Dec;49(6):10202. Cross Ref link Pubmed link
  • 355  Duvic M, Lowe L, Rapini RP, Rodriguez S, Levy ML. Eruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol 1989 Mar;125(3):397401. Cross Ref link Pubmed link
  • 356  Betlloch I, Amador C, Chiner E, Pasquau F, Calpe JL, Vilar A. Eruptive melanocytic nevi in human immunodeficiency virus infection. Int J Dermatol 1991 Apr;30(4):303. Cross Ref link Pubmed link
  • 357  Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006 May;154(5):8804. Cross Ref link Pubmed link
  • 358  de Boer NK, Kuyvenhoven JP. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient. Inflamm Bowel Dis 2011 Jun;17(6):E26. Cross Ref link Pubmed link
  • 359  Braun SA, Helbig D, Frank J, Hanneken S. [Eruptive melanocytic nevi during azathioprine therapy in myasthenia gravis.] Hautarzt 2012 Oct;63(10):7569. Cross Ref link Pubmed link
  • 360  Martin Hernandez JM, Donat Colomer J, Monteagudo Castro C, et al. [Acral eruptive nevi after chemotherapy in children with acute lymphoblastic leukemia.] Anales Pediatr (Barcelona) 2006 Sep;65(3):2602. Cross Ref link
  • 361  Piaserico S, Alaibac M, Fortina AB, Peserico A. Clinical and dermatoscopic fading of post‐transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol 2006 Feb;54(2):33840. Cross Ref link Pubmed link
  • 362  Sekulic A, Colgan MB, Davis MD, DiCaudo DJ, Pittelkow MR. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol 2010 Nov;163(5):10958. Cross Ref link Pubmed link
  • 363  John JK, Smalley KS. Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? Exp Rev Anticancer Ther 2011 May;11(5):71114. Cross Ref link
  • 364  Ameen M. The impact of human immunodeficiency virus‐related diseases on pigmented skin types. Br J Dermatol 2013 Oct;169 Suppl. 3:1118. Cross Ref link Pubmed link
  • 365  Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV‐infected patients. Nature Rev Clin Oncol 2014 Apr;11(4):22338. Cross Ref link
  • 366  Gramolelli S, Schulz TF. The role of Kaposi sarcoma‐associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol 2015 Jan;235(2):36880. Cross Ref link Pubmed link
  • 367  Frances C, Marcelin AG, Legendre C, et al. The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant 2009 Nov;9(11):25806. Cross Ref link Pubmed link
  • 368  Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant 2013 Feb;13 Suppl. 3:6777; quiz ‐8. Cross Ref link Pubmed link
  • 369  Lebbe C, Porcher R, Marcelin AG, et al. Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients. Am J Transplant 2013 Jan;13(1):20713. Cross Ref link Pubmed link
  • 370  Riva G, Luppi M, Barozzi P, Forghieri F, Potenza L. How I treat HHV8/KSHV‐related diseases in posttransplant patients. Blood 2012 Nov 15;120(20):41509. Cross Ref link Pubmed link
  • 371  Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma‐specific survival independent of stage. J Invest Dermatol 2013 Mar;133(3):6426. Cross Ref link Pubmed link
  • 372  Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet 2002 Feb 9;359(9305):4978. Cross Ref link Pubmed link
  • 373  Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 2012 Aug 1;131(3):E3268. Cross Ref link Pubmed link
  • 374  Asgari MM, Sokil MM, Warton EM, Iyer J, Paulson KG, Nghiem P. Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol 2014 Jul;150(7):71623. Cross Ref link Pubmed link
  • 375  Clarke CA, Robbins HA, Tatalovich Z, et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 2015 Feb;107(2). Cross Ref link
  • 376  Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers 2014;6(3):132850. Cross Ref link Pubmed link
  • 377  Koljonen V, Kukko H, Pukkala E, et al. Chronic lymphocytic leukaemia patients have a high risk of Merkel‐cell polyomavirus DNA‐positive Merkel‐cell carcinoma. Br J Cancer 2009 Oct 20;101(8):14447. Cross Ref link Pubmed link
  • 378  Kanitakis J. Rare skin cancers. Cancer Treat Res 2009;146:3238. Cross Ref link Pubmed link
  • 379  Arron ST, Canavan T, Yu SS. Organ transplant recipients with Merkel cell carcinoma have reduced progression‐free, overall, and disease‐specific survival independent of stage at presentation. J Am Acad Dermatol 2014 Oct;71(4):68490. Cross Ref link Pubmed link
  • 380  Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid‐organ transplantation among elderly adults. Int J Cancer 2010 Apr 1;126(7):172431. Pubmed link
  • 381  Izikson L, Nornhold E, Iyer JG, Nghiem P, Zeitouni NC. Merkel cell carcinoma associated with HIV: review of 14 patients. AIDS (London) 2011 Jan 2;25(1):11921. Cross Ref link
  • 382  Wieland U, Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV‐positive individuals. Curr Opin Oncol 2011 Sep;23(5):48893. Cross Ref link Pubmed link
  • 383  Tadmor T, Aviv A, Polliack A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties. Ann Oncol 2011 Feb;22(2):2506. Cross Ref link Pubmed link
  • 384  Koljonen V, Kukko H, Tukiainen E, et al. Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. Cancer Epidemiol 2010 Feb;34(1):625. Cross Ref link Pubmed link
  • 385  Lok C, Viseux V, Denoeux JP, Bagot M. Post‐transplant cutaneous T‐cell lymphomas. Crit Rev Oncol/Hematol 2005 Oct;56(1):13745. Cross Ref link
  • 386  Pomerantz RG, Campbell LS, Jukic DM, Geskin LJ. Posttransplant cutaneous T‐cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Arch Dermatol 2010 May;146(5):51316. Cross Ref link Pubmed link
  • 387  Seckin D, Barete S, Euvrard S, et al. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant 2013 Aug;13(8):214653. Cross Ref link Pubmed link
  • 388  Ravat FE, Spittle MF, Russell‐Jones R. Primary cutaneous T‐cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 2006 Apr;54(4):66875. Cross Ref link Pubmed link
  • 389  Beylot‐Barry M, Vergier B, Masquelier B, et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999 Oct;23(10):120816. Cross Ref link Pubmed link
  • 390  Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006 Feb;54(2):189206; quiz 7–10. Cross Ref link Pubmed link
  • 391  Zhang P, Chiriboga L, Jacobson M, et al. Mycosis fungoides like T‐cell cutaneous lymphoid infiltrates in patients with HIV infection. Am J Dermatopathol 1995 Feb;17(1):2935. Cross Ref link Pubmed link
  • 392  Bachelez H, Hadida F, Parizot C, et al. Oligoclonal expansion of HIV‐specific cytotoxic CD8 T lymphocytes in the skin of HIV‐1‐infected patients with cutaneous pseudolymphoma. J Clin Invest 1998 Jun 1;101(11):250616. Cross Ref link Pubmed link
  • 393  Chang MB, Weaver AL, Brewer JD. Cutaneous T‐cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo Clinic. Int J Dermatol 2014 Aug;53(8):96670. Cross Ref link Pubmed link
  • 394  Harwood CA, Swale VJ, Bataille VA, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001 Feb;116(2):24653. Cross Ref link Pubmed link
  • 395  Harwood CA, McGregor JM, Swale VJ, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol 2003 Mar;48(3):4018. Cross Ref link Pubmed link
  • 396  Mahomed F, Blok J, Grayson W. The squamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases. J Clin Pathol 2008 Mar;61(3):3615. Cross Ref link Pubmed link
  • 397  Shiels MS, Engels EA. Increased risk of histologically defined cancer subtypes in human immunodeficiency virus‐infected individuals: clues for possible immunosuppression‐related or infectious etiology. Cancer 2012 Oct 1;118(19):486976. Cross Ref link Pubmed link
  • 398  Dewan P, Jawad A, Goldsmith P, Harwood C, Cerio R. Melanoma in patients with rheumatoid arthritis treated with antitumour necrosis factor: cause or coincidence? Report of two cases. Br J Dermatol 2009 Dec;161(6):141214. Cross Ref link Pubmed link
  • 399  Mansfield AS, Rabe KG, Slager SL, et al. Skin cancer surveillance and malignancies of the skin in a community‐dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pract 2014 Jan;10(1):e14. Cross Ref link Pubmed link
  • 400  Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC. The Muir–Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol 1997 Sep;24(8):51118. Cross Ref link Pubmed link
  • 401  Bhatia K, Shiels MS, Berg A, Engels EA. Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review. Curr Opin Oncol 2012 Sep;24(5):53746. Cross Ref link Pubmed link
  • 402  Kemp JD, Stenn KS, Arons M, Fischer J. Metastasizing atypical fibroxanthoma. Coexistence with chronic lymphocytic leukemia. Arch Dermatol 1978 Oct;114(10):15335. Cross Ref link Pubmed link
  • 403  Perrett CM, Cerio R, Proby CM, Harwood CA. Atypical fibroxanthoma in a renal transplant recipient. Histopathology 2005 Sep;47(3):3267. Cross Ref link Pubmed link
  • 404  Cooper JZ, Newman SR, Scott GA, Brown MD. Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): report of five cases. Dermatol Surg 2005 Feb;31(2):2215; discussion 5. Cross Ref link Pubmed link
  • 405  Colgan MB, Brewer JD, Weaver AL, Roenigk RK, Otley CC. Atypical fibroxanthoma in the setting of chronic lymphocytic leukemia and other non‐Hodgkin lymphomas. Dermatol Surg 2011 May;37(5):6716. Cross Ref link Pubmed link
  • 406  Kubica AW, Rose PS, Weaver AL, Brewer JD. Increased metastasis of malignant fibrous histiocytoma in patients with chronic lymphocytic leukemia and non‐Hodgkin lymphoma. Mayo Clin Proc 2011 Aug;86(8):73843. Cross Ref link Pubmed link
  • 407  Paquet P, Pierard GE. Invasive atypical fibroxanthoma and eruptive actinic keratoses in a heart transplant patient. Dermatology 1996;192(4):41113. Cross Ref link Pubmed link
  • 408  Lai KN, Lai FM, King WW, et al. Dermatofibrosarcoma protuberans in a renal transplant patient. Australian New Zealand J Surg 1995 Dec;65(12):9002. Cross Ref link
  • 409  Picciotto F, Basolo B, Massara C, et al. Dermatofibrosarcoma protuberans at the site of arteriovenous fistula in a renal transplant recipient. Transplantation 1999 Oct 15;68(7):10745. Cross Ref link Pubmed link
  • 410  Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004 Apr;30(4 Pt 2):64250. Pubmed link
  • 411  Zwald FO, Christenson LJ, Billingsley EM, et al. Melanoma in solid organ transplant recipients. Am J Transplant 2010 May;10(5):1297304. Cross Ref link Pubmed link
  • 412  Geusau A, Pohanka E. Aftercare – a multi‐disciplinary approach. Cancer Treat Res 2009;146:40515. Cross Ref link Pubmed link
  • 413  Morelon E, Mahe E, Touraine J‐L. The role of the transplant physician in the management of skin cancers after organ transplantation. Skin cancer after organ transplantation. Cancer Treatment Res 2009;146:37790. Cross Ref link
  • 414  Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002 Jul;47(1):117; quiz 8–20. Cross Ref link Pubmed link
  • 415  Bangash HK, Colegio OR. Management of non‐melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treatment Options Oncol 2012 Sep;13(3):35476 (review). Cross Ref link
  • 416  de Graaf YG, Basdew VR, van Zwan‐Kralt N, Willemze R, Bavinck JN. The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation. Br J Dermatol 2006 Mar;154(3):4937. Cross Ref link Pubmed link
  • 417  Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 2008 Aug 15;86(3):4239. Cross Ref link Pubmed link
  • 418  Wulf HC, Pavel S, Stender I, Bakker‐Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006;86(1):258. Pubmed link
  • 419  Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high‐risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J Surg Oncol 2011;9:80. Cross Ref link Pubmed link
  • 420  Allen JE, Stolle LB. Utility of sentinel node biopsy in patients with high‐risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2015 Feb;41(2):197200. Cross Ref link Pubmed link
  • 421  Jennings L, Schmults CD. Management of high‐risk cutaneous squamous cell carcinoma. J Clin Aesthetic Dermatol 2010 Apr;3(4):3948.
  • 422  Jambusaria‐Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high‐risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009 Apr;35(4):57485. Cross Ref link Pubmed link
  • 423  Veness MJ, Harris D. Role of radiotherapy in the management of organ transplant recipients diagnosed with non‐melanoma skin cancers. Australasian Radiol 2007 Feb;51(1):1220. Cross Ref link
  • 424  Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal‐transplant recipients. N Engl J Med 2005 Mar 31;352(13):131723. Cross Ref link Pubmed link
  • 425  Boratynska M, Zmonarski SC, Klinger M. Reccurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006 Dec 20;6(13–14):201822. Cross Ref link Pubmed link
  • 426  Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006 Sep;6(9):21648. Cross Ref link Pubmed link
  • 427  Nicholson S. Management of metastatic skin cancers in organ transplant recipients. Cancer Treat Res 2009;146:46781. Cross Ref link Pubmed link
  • 428  Wells JL, 3rd, Shirai K. Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients. Am J Clin Oncol 2012 Oct;35(5):498503. Cross Ref link Pubmed link
  • 429  Bejar C, Maubec E. Therapy of advanced squamous cell carcinoma of the skin. Curr Treatment Options Oncol 2014 Jun;15(2):30220. Cross Ref link
  • 430  Martinez JC, Otley CC, Okuno SH, Foote RL, Kasperbauer JL. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg 2004 Apr;30(4 Pt 2):67986. Pubmed link
  • 431  Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR‐targeted therapy. Pathol Res Pract 2011;207(6):33742. Cross Ref link Pubmed link
  • 432  Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single‐agent cetuximab. Anti‐Cancer Drugs 2007 Aug;18(7):8279.
  • 433  Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transpl 2007 Dec;26(12):13404. Cross Ref link
  • 434  Lewis CM, Glisson BS, Feng L, et al. A Phase II Study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012 Mar 1;18(5):143546. Cross Ref link Pubmed link
  • 435  Heath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiation Oncol Biol Phys 2013 Apr 1;85(5):127581. Cross Ref link
  • 436  Gordon LG, Scuffham PA, van der Pols JC, McBride P, Williams GM, Green AC. Regular sunscreen use is a cost‐effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol 2009 Dec;129(12):276671. Cross Ref link Pubmed link
  • 437  Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007 Oct 15;179(8):520410. Cross Ref link Pubmed link
  • 438  Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009 Feb 12;113(7):15818. Cross Ref link Pubmed link
  • 439  Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014 Jul 1;32(19):e6971. Cross Ref link Pubmed link
  • 440  Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M. Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol 2011 Nov 10;29(32):e7924. Cross Ref link Pubmed link
  • 441  Kanitakis J, Baldassini S, Lora V, Euvrard S. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol 2010 Mar–Apr;20(2):16771. Pubmed link
  • 442  Otley CC. Pre‐transplantation dermatologic screening and prophylaxis. The SCOPE Collaborative Group In: Rosen T, ed. Cancer Treatment and Research, vol. 146. London: Springer, 2009. Pubmed link
  • 443  European Best Practice Guidelines for Renal Transplantation. Section IV: Long‐term management of the transplant recipient. Nephrol Dial Transplant 2002;17 Suppl. 4:167. Cross Ref link
  • 444  KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009 Nov;9 Suppl. 3:S1155.
  • 445  Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal‐cell and squamous‐cell carcinomas of the skin: a randomised controlled trial. Lancet 1999 Aug 28;354(9180):7239. Cross Ref link Pubmed link
  • 446  Green A, Harwood C, Lear J, Proby C, Sinnya S, Soyer H. Skin cancer prevention: recent evidence from randomized controlled trials. Curr Dermatol Rep 2012;1(3):12330. Cross Ref link
  • 447  Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993 Oct 14;329(16):114751. Cross Ref link Pubmed link
  • 448  Ulrich C, Johannsen A, Rowert‐Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo‐controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010 Jul–Aug;20(4):4828. Pubmed link
  • 449  Loescher LJ, Hansen C, Hepworth JT, Quale L, Sligh J. A preliminary study of a video intervention to inform solid organ transplant recipients about skin cancer. Transplant Proc 2013 Nov;45(9):31879. Cross Ref link Pubmed link
  • 450  Reichrath J. Dermatologic management, sun avoidance and vitamin D status in organ transplant recipients (OTR). J Photochem Photobiol B 2010 Nov 3;101(2):1509. Cross Ref link Pubmed link
  • 451  Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013 Sep;169(3):50218. Cross Ref link Pubmed link
  • 452  Criscione VD, Weinstock MA, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009 Jun 1;115(11):252330. Cross Ref link Pubmed link
  • 453  Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient‐oriented perspective. Arch Dermatol 1991 Jul;127(7):102931. Cross Ref link Pubmed link
  • 454  van Zuuren EJ, Posma AN, Scholtens RE, Vermeer BJ, van der Woude FJ, Bouwes Bavinck JN. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol 1994 Nov;31(5 Pt 1):7604. Cross Ref link Pubmed link
  • 455  Amini S, Viera MH, Valins W, Berman B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthetic Dermatol 2010 Jun;3(6):2034.
  • 456  Kurwa HA, Yong‐Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5‐fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999 Sep;41(3 Pt 1):41418. Cross Ref link Pubmed link
  • 457  Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long‐term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 1997 Mar;23(3):1916. Pubmed link
  • 458  Perrett CM, McGregor JM, Warwick J, et al. Treatment of post‐transplant premalignant skin disease: a randomized intrapatient comparative study of 5‐fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007 Feb;156(2):3208. Cross Ref link Pubmed link
  • 459  Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double‐blind, parallel group, vehicle‐controlled trials. J Am Acad Dermatol 2004 May;50(5):71421. Cross Ref link Pubmed link
  • 460  Stockfleth E, Sterry W, Carey‐Yard M, Bichel J. Multicentre, open‐label study using imiquimod 5% cream in one or two 4‐week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol 2007 Dec;157 Suppl 2:416. Cross Ref link Pubmed link
  • 461  Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo‐controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007 Dec;157 Suppl. 2:2531. Cross Ref link Pubmed link
  • 462  Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high‐risk renal transplant recipients: randomized, double‐blind, placebo‐controlled trial. Arch Dermatol 2005 Aug;141(8):98593. Pubmed link
  • 463  Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004 Jul;151(1):196200. Cross Ref link Pubmed link
  • 464  Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004 Jan 15;77(1):11521. Cross Ref link Pubmed link
  • 465  Piaserico S, Belloni Fortina A, Rigotti P, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007 Jul–Aug;39(6):184750. Cross Ref link Pubmed link
  • 466  Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 2010 May;36(5):6528. Cross Ref link Pubmed link
  • 467  de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does not prevent cutaneous squamous‐cell carcinoma in organ‐transplant recipients: results of a randomized‐controlled trial. J Invest Dermatol 2006 Mar;126(3):56974. Cross Ref link Pubmed link
  • 468  Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation 2009 Jan 27;87(2):23342. Cross Ref link Pubmed link
  • 469  Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant Int 2012 Apr;25(4):41623. Cross Ref link
  • 470  Gutierrez‐Dalmau A, Sanchez‐Fructuoso A, Sanz‐Guajardo A, et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 2005 Nov;37(9):38368. Cross Ref link Pubmed link
  • 471  Yaich S, Charfeddine K, Zaghdane S, et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transplant Proc 2012 Nov;44(9):28246. Cross Ref link Pubmed link
  • 472  de Fijter JW. Use of proliferation signal inhibitors in non‐melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007 May;22 Suppl. 1:i236. Cross Ref link Pubmed link
  • 473  Rival‐Tringali AL, Euvrard S, Decullier E, Claudy A, Faure M, Kanitakis J. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post‐transplant cutaneous squamous cell carcinomas. Anticancer Res 2009 Jun;29(6):192732. Pubmed link
  • 474  Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus‐based immunosuppression in long‐term renal transplant recipients: reduced rate of (pre‐) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor‐blinded, controlled clinical trial. Am J Transplant 2010 Jun;10(6):138593. Cross Ref link Pubmed link
  • 475  Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin‐cancer prevention in kidney transplantation. N Engl J Med 2012 Jul 26;367(4):32939. Cross Ref link Pubmed link
  • 476  Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012 May;12(5):114656. Cross Ref link Pubmed link
  • 477  Hoogendijk‐van den Akker JM, Harden PN, Hoitsma AJ, et al. Two‐year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013 Apr 1;31(10):131723. Cross Ref link Pubmed link
  • 478  Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R. Non‐melanoma skin cancer is reduced after switch of immunosuppression to mTOR‐inhibitors in organ transplant recipients. J Deutschen Dermatol Gesellsch 2014 Jun;12(6):4808.
  • 479  Tavadia S, Dawn G, Payne C, Ramrakha‐Jones V, Murday A, Holmes S. Skin‐cancer awareness in Scottish cardiac transplant recipients. Clin Exp Dermatol 2006 May;31(3):3547. Cross Ref link Pubmed link
  • 480  Colegio OR, Hanlon A, Olasz EB, Carucci JA. Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients. J Clin Oncol 2013 Sep 10;31(26):32978. Cross Ref link Pubmed link
  • 481  Brewer JD. Skin cancer in patients with non‐Hodgkin's lymphoma. Exp Rev Dermatol 2010;5:52533. Cross Ref link
  • 482  Karayannopoulou G, Euvrard S, Kanitakis J. Differential expression of p‐mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ‐transplant recipients. Anticancer Res 2013 Sep;33(9):371114. Pubmed link
  • 483  Knoll GA, Koko MB, Lick RM, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta‐analysis of individual patient data. BMJ 2014 Nov 24;349.
  • 484  Cheepala SB, Syed Z, Trutschl M, Cvek U, Clifford JL. Retinoids and skin: microarrays shed new light on chemopreventive action of all‐trans retinoic acid. Mol Carcinogen 2007 Aug;46(8):6349. Cross Ref link
  • 485  Hardin J, Mydlarski PR. Systemic retinoids: chemoprevention of skin cancer in transplant recipients. Skin Ther Lett 2010 Jul–Aug;15(7):14.
  • 486  Lien MH, Fenske NA, Glass LF. Advances in the chemoprevention of non‐melanoma skin cancer in high‐risk organ transplant recipients. Semin Oncol 2012 Apr;39(2):1348. Cross Ref link Pubmed link
  • 487  De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004 Apr;30(4 Pt 2):65661. Pubmed link
  • 488  Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988 Sep;68(257):71725. Pubmed link
  • 489  Kelly JW, Sabto J, Gurr FW, Bruce F. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991 Nov 30;338(8779):1407. Cross Ref link Pubmed link
  • 490  Gibson GE, O'Grady A, Kay EW, Murphy GM. Low‐dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998 Jan;10(1):427. Cross Ref link Pubmed link
  • 491  McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low‐dose acitretin. Br J Dermatol 1999 Apr;140(4):65660. Cross Ref link Pubmed link
  • 492  George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non‐melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002 Nov;43(4):26973. Cross Ref link Pubmed link
  • 493  de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003 Sep;49(3):40712. Cross Ref link Pubmed link
  • 494  Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double‐blind, placebo‐controlled study. J Clin Oncol 1995 Aug;13(8):19338. Pubmed link
  • 495  Martinez JC, Otley CC, Euvrard S, Arpey CJ, Stasko T. Complications of systemic retinoid therapy in organ transplant recipients with squamous cell carcinoma. Dermatol Surg 2004 Apr;30(4 Pt 2):6626. Pubmed link
  • 496  Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001 Mar 24;357(9260):9269. Cross Ref link Pubmed link
  • 497  Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant 2011 Jul–Aug;25(4):5418. Cross Ref link Pubmed link
  • 498  Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg 2013 Apr;39(4):63445. Cross Ref link Pubmed link
  • 499  Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012 Nov 1;118(21):5395402. Cross Ref link Pubmed link
  • 500  Webster AC, Wong G, Craig JC, Chapman JR. Managing cancer risk and decision making after kidney transplantation. Am J Transplant 2008 Nov;8(11):218591. Cross Ref link Pubmed link
  • 501  Garg S, Carroll RP, Walker RG, Ramsay HM, Harden PN. Skin cancer surveillance in renal transplant recipients: re‐evaluation of U.K. practice and comparison with Australian experience. Br J Dermatol 2009 Jan;160(1):1779. Cross Ref link Pubmed link
  • 502  Christenson LJ, Geusau A, Ferrandiz C, et al. Specialty clinics for the dermatologic care of solid‐organ transplant recipients. Dermatol Surg 2004 Apr;30(4 Pt 2):598603. Pubmed link
  • 503  Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients – where do we stand today? Am J Transplant 2008 Nov;8(11):21928. Cross Ref link Pubmed link
  • 504  Urwin HR, Jones PW, Harden PN, et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 2009 Jun 15;87(11):166771. Cross Ref link Pubmed link
  • 505  Ismail F, Mitchell L, Casabonne D, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006 Nov;155(5):91625. Cross Ref link Pubmed link
  • 506  Robinson JK, Turrisi R, Mallett KA, et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self‐examination for squamous cell carcinoma detection. Arch Dermatol 2011 Jun;147(6):68995. Cross Ref link Pubmed link
  • 507  Trinh N, Novice K, Lekakh O, Means A, Tung R. Use of a brief educational video administered by a portable video device to improve skin cancer knowledge in the outpatient transplant population. Dermatol Surg 2014 Nov;40(11):12339. Cross Ref link Pubmed link
  • 508  Clowers‐Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. Arch Dermatol 2006 Jun;142(6):71218. Pubmed link
  • 509  Thomas BR, Barnabas A, Agarwal K, et al. Patient perception of skin‐cancer prevention and risk after liver transplantation. Clin Exp Dermatol 2013 Dec;38(8):8516. Cross Ref link Pubmed link
  • 510  Kauffman HM, Woodle ES, Cole EH, Paykin C. Transplant recipient's knowledge of posttransplant malignancy risk: implications for educational programs. Transplantation 2008 Apr 15;85(7):92833. Cross Ref link Pubmed link
  • 511  Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000 Oct;11 Suppl. 15:S186. Pubmed link
  • 512  Gogia R, Binstock M, Hirose R, Boscardin WJ, Chren MM, Arron ST. Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation. J Am Acad Dermatol 2013 Apr;68(4):58591. Cross Ref link Pubmed link
  • 513  National Institute for Health and Care Excellence (NICE). NICE The Guidelines Manual. London: NICE, 2006.
  • 514  Magro F, Peyrin‐Biroulet L, Sokol H, et al. Extra‐intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohn Colitis 2014 Jan;8(1):3144. Cross Ref link
  • 515  Skin Care in Organ Transplant Patients (SCOPE). Skin Care in Organ Transplant Patients (cited 2015 30/07/2015) http://www.scopenetwork.org (last accessed September 2015).
  • 516  International Transplant Skin Cancer Collaborative (ITSCC) (cited 2015 30/07/2015) http://www.itscc.org/ (last accessed September 2015).
  • 517  British Society for Skin Care in Immunosuppressed Individuals (BSSCII) (cited 2015 30/07/2015) www.bsscii.org.uk (last accessed September 2015).
  • 518  Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre‐ and post‐HAART eras: a systematic review and meta‐analysis of cohort studies. PLoS One 2014;9:e95096.
  • 519  de Boer NK, Kuyvenhoven JP. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient. Inflamm Bowel Dis 2011;17:E26.
  • 520  Kim JK, Carmody IC, Cohen AJ, Loss GE. Donor transmission of malignant melanoma to a liver graft recipient: case report and literature review. Clin Transplant 2009;23:5714.